Predicting diabetes after kidney transplant using microRNA
Official title: Predicting Outcomes in Posttransplant Diabetes Mellitus Via microRNA
Run by University Hospital, Martin · NCT07055984 · Data updated 2026-11-12
We will test whether specific microRNA patterns measured three months after a kidney transplant can predict which adult transplant recipients will develop diabetes in the following one to two years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 130 (estimated) |
| Sponsor | University Hospital, Martin Academic / other |
| Locations | 2 sites (Martin and 1 other locations) |
| Status | Recruiting |
| Started | April 28, 2025 |
| Main results expected | April 28, 2028 |
| Study ends | April 28, 2029 |
| Registry record updated | July 9, 2025 |
| Trial ID | NCT07055984 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult kidney transplant recipients without pre-existing type 1 or type 2 diabetes who can give informed consent and attend follow-up visits.
✕Probably not a fit
Patients with pre-existing diabetes, prior organ transplants, severe comorbidities that confound PTDM assessment (such as pancreatic disease), or inability to consent are unlikely to benefit from the study's predictive biomarkers.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will collect blood samples from adult kidney transplant recipients without prior diabetes and measure microRNA profiles three months after transplantation. Participants will be followed for one to two years to record new-onset post-transplant diabetes mellitus (PTDM) and related clinical events. Researchers will combine microRNA data with traditional risk factors — including age, immunosuppressive regimen, obesity, and CMV infection — to develop predictive models. The aim is to find early molecular indicators that could prompt closer monitoring or preventive measures.
Why it matters
Potential benefit: If successful, the approach could allow earlier identification of patients at risk for post-transplant diabetes, enabling timely monitoring and individualized preventive steps to reduce complications.
How similar studies have gone: Some pilot studies have reported associations between microRNA signatures and diabetes risk after transplant, but larger validation studies remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients undergoing kidney transplantation. * Absence of pre-existing type 1 or type 2 diabetes mellitus. * Willingness to provide informed consent and comply with study procedures. Exclusion Criteria: * Pre-existing type 1 or type 2 diabetes mellitus. * Previous organ transplantation. * Severe comorbidities that could confound the assessment of PTDM (e.g., pancreatic disease). * Inability to provide informed consent.
Where it's running
-
Transplant-nephorlogy department
Martin, Slovakia Recruiting -
University hospital Martin
Martin, Slovakia Recruiting
Study contacts
- Study coordinator: Ivana Dedinska, prof, MD, PhD.
- Email: ivana.dedinska@uniba.sk
- Phone: +421 43 4203 920
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing empagliflozin and linagliptin for diabetes management in kidney transplant recipients
This study is testing whether the diabetes medications empagliflozin and linagliptin can help kidney transplant recipients manage their blood sugar and improve their overall health.
-
Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing
A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.
-
DiaFootCare: a mobile app to help adults with diabetic foot ulcers manage self-care in Oman
A mobile app called DiaFootCare will be tested to see if it helps adults with diabetic foot ulcers in Oman take better care of themselves and improve healing compared with usual care.
-
Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes
This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.
-
SugarVita 2.0: a 12-week digital game for adults with type 2 diabetes
This 12-week pilot tests SugarVita 2.0, a serious digital game, to see if it helps adults with type 2 diabetes manage their condition and feel more confident.
-
Linking social care with healthcare to help manage chronic diseases
This trial tests whether pairing patients with trained community health workers can help them get transportation, healthy food, information, and better access to care to improve health in conditions like hypertension, diabetes, and high cholesterol.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.